Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 3 1Phase 1/2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Other solid neoplasm 2Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Phase IB 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × defactinib × Gynecologic × Clear all
NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

NCT02943317 2019-04-30

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Verastem, Inc.

Phase 1 Terminated
98 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01778803 2017-05-17

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Verastem, Inc.

Phase 1 Completed
22 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡